Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

NCT05784974 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT05784974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2023
Completion date
May 1, 2028
Enrollment
37 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer